How Nanotech Could Make Taking Insulin Safer and Easier
People with diabetes may soon be able to replace injections with more palatable oral forms of insulin, such as sugar-free...
Dr Nicholas Hunt is a senior lecturer in the School of Medical Science at the University of Sydney and leader at the Biogerontology laboratory at the ANZAC Research Institute. His research interests centre around the development of new nanomaterials for use and translation in clinical medicine. He has worked on the development of quantum dots and organic nanoparticles for biological applications including the transportation of pharmaceutical agents, biologics, RNA and gene therapy.
Dr Hunt is co-founder and CEO of Endo Axiom, which will be taking these therapeutics to clinical trials.
Dr Hunt's research has been supported by the Australian Diabetes Society, the University of Sydney, the Sydney Medical School Foundation, the National Health and Medical Research Council (NHMRC), the Medical Research Future Fund (MRFF), Therapeutic Innovation Australia and the Caenorhabditis Genetics Centre.
People with diabetes may soon be able to replace injections with more palatable oral forms of insulin, such as sugar-free...
Impakter informs you through the ESG news site and empowers your business CSRD compliance and ESG compliance with its Klimado SaaS ESG assessment tool marketplace that can be found on: www.klimado.com
Registered Office Address
Klimado GmbH
Niddastrasse 63,
60329, Frankfurt am Main, Germany
IMPAKTER is a Klimado GmbH website
Impakter is a publication that is identified by the following International Standard Serial Number (ISSN) is the following 2515-9569 (Printed) and 2515-9577 (online – Website).
Office Hours - Monday to Friday
9.30am - 5.00pm CEST
stories [at] impakter.com
© 2025 IMPAKTER. All rights reserved.